MammaPrint® – Added value of using gene-expression signature for adjuvant chemotherapy decisions in early breast cancer assessment (OTCA04)


Original post, click here
Share this...
Tweet about this on TwitterShare on FacebookShare on LinkedInEmail this to someoneShare on Google+Share on RedditPin on Pinterest

Final project plan for Other Technologies CA on MammaPrint® – Added value of using gene-expression signature for adjuvant chemotherapy decisions in early breast cancer assessment (OTCA04)

This is the final project plan of the Other Technologies CA on MammaPrint® – Added value of using gene-expression signature for adjuvant chemotherapy decisions in early breast cancer assessment (OTCA04).

Project Plan